About Market Research Report Store Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests. Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.
Merck KGaA (MRK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile ID: 269370 December 2016 Region: Germany 284 pages GlobalData Single User License - $250.00 Corporate Users License - $500.00
Enterprise Wide License - $750.00
MRRS adds "Merck KGaA (MRK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile" latest studies, published in December 2016. It is a professional and in-depth study.
Summary Merck KGaA (Merck) is a pharmaceutical and chemical company, which operates its business in three markets namely, healthcare market, performance materials market and life sciences market. Its business operations include promoting prescription drugs of chemical and biological origin and over-the-counter products for preventive health care and the self-treatment of minor ailments (healthcare market); identifying, developing and manufacturing biotech and pharmaceutical drugs and general laboratory applications (life sciences market); and developing liquid crystal mixtures and cosmetic active ingredients (performance materials market). The company has operations in over 66 countries spread across Europe, North America, South America, Africa, Asia and Australia. It is a subsidiary of E. Merck KG and is headquartered in Darmstadt, Germany. Merck KGaA (MRK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope – Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. – Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. – Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. – Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. – Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector. – Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations. – Key Employees – A list of the key executives of the company. – Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company. – Key Competitors – A list of the key competitors of the company. – Key Recent Developments – A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements – The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period. Understand the company’s business segments’ expansion / divestiture strategy – The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy. Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company – Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios. Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. – The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company – Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research – Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.
Table Of Contents Table of Contents 2 List of Tables 7
List of Figures 12 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 13 Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 14 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 15 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 16 Merck KGaA, Medical Devices Deals, 2010 to YTD 2016 18 Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 19 Merck KGaA, Pharmaceuticals & Healthcare, Deal Details 32 Asset Purchase 32 Merck KgaA Acquires SevenSeas Original Brand 32 Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 33 Venture Financing 34 Asceneuron Raises USD30.6 Million in Series A Financing 34 TocopheRx Raises US$3.3 Million In Seed Financing 36 Asceneuron Raises US$6.4 Million In Seed Financing 37 VAXIMM Secures US$8 Million In Venture Financing 38 Private Equity 40 Merck Sells Its Pharma Operations To Nkunzi Investment And Omame 40 Partnerships 41 Merck Enters Into Licensing Agreement With BeiGene For BeiGene-290 41 Proteome Sciences Enters Into License Agreement With Sigma-Aldrich 42 PCAS Enters into Distribution Agreement with MilliporeSigma 43 MilliporeSigma Enters into Research Agreement with International Vaccine Institute 44 Selvita Enters into Agreement with Merck 45 Merck Enters into Agreement with University of Buea 46 Merck, Pfizer and Verastem Enter into Agreement 47 Merck Enters into Research Agreement with European Molecular Biology Labs 48 Threshold Pharma and Merck Terminates Agreement 49 Merck, Pfizer and Syndax Pharma Enter into Agreement 50 Selvita Enters into Development and Commercialization Agreement with Merck 51 Biothera Pharma Enters into Partnership with Merck 52 Sigma-Aldrich Enters into Agreement with Sanger Institute 53
Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 54 Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 55 Aeterna Zentaris Enters into Agreement with EMD Serono 56 Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 57 Lucigen Enters into Distribution Agreement with Sigma-Aldrich 58 Merck Serono Enters into Co-Development Agreement with MMV 59 Sigma-Aldrich Enters into Distribution Agreement with Roche 60 Merck Serono Terminates Agreement with Bristol-Myers Squibb 61 Merck Enters into Development Agreement with Precision Biologics 63 Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 64 Pfizer Enters into Co-Development Agreement with Merck 65 BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 67 Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 68 Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 69 Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 70 Lupin Enters into Co-Development Agreement with Merck Serono 71 Merck Serono Extends R&D Agreement with San Raffaele 72 Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 73 Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 74 Bionovis Enters into Agreement with Merck 75 EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 76 EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 78 KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 79 Biopharm Enters Into Research Agreement With Merck Serono 80 Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 81 EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 83 Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 84 Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 85 Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 87
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 88 Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 90 Isu Abxis Enters into Co-Development Agreement with Merck 91 Luminex Extends Distribution Agreement With EMD Millipore 92 Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 93 Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 95 Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 96 Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 97 Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 99 EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 100 AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 101 EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 102 Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 103 Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 104 Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 105 TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 106 Genovis Enters Into Distribution Agreement With Sigma-Aldrich 107 Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 108 EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 110 EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 111 Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 112 Mapi Pharma Amends Co-Development Agreement with Merck 114 TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 115 Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 116 IntelliCell BioSciences Enters Into Co-Marketing Agreement With Millipore 118
f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 119 Emmaus Medical Terminates Co-Promotion Agreement With EMD Serono For Zorbtive 120 BASF Enters Into Distribution Agreement With Sigma-Aldrich 121 Lead Discovery Center Enters Into Agreement With Merck Serono 122 Merck Serono Enters Into Research Agreement With Philochem 123 Merck Serono Enters Into Co-Development Agreement With Sanofi-aventis 124 EMD Serono Enters Into Co-Marketing Agreement With Tercica 125 Merck Serono Extends Co-Development Agreement With INSpe And Department Of Neurology Of San Raffaele 126 Evotec Enters Into Collaboration With Merck KGaA 127 Domainex Enters Into Collaboration With Sigma-Aldrich 128 Sigma Life Science Enters Into Co-Marketing Agreement With JAX 129 Sigma Life Science Enters Into An Agreement With Autism Speaks 130 Ablynx Enters Into Second Co-Discovery And Co-Development Agreement With Merck Serono 131 EDELRIS Enters Into Collaboration With Merck Serono 132 Generex Biotech Enters Into Co-Marketing Agreement With Merck 133 Sigma Life Science Enters Into An Agreement With SwitchGear 134 Millipore Enters Into Collaboration With BioOutsource 135 Sigma-Aldrich Enters Into Distribution Agreement With New Mexico Highlands 136 Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim 137 Swedish Orphan Biovitrum Expands Distribution Agreement With Merck Serono 138 Eden Biodesign Enters Into A Collaboration With Millipore 139 Sigma-Aldrich Enters Into Commercialization Agreement With Pfizer 140 Sigma-Aldrich Enters Into Distribution Agreement With Eka Chemicals 141 BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono 142 Cancer Research And Cancer Research Technology Enter Into An Agreement With Merck 143 Licensing Agreements 144 Merck Enters into Licensing Agreement with Weizmann Institute of Science 144 Merck Serono Terminates its Licensing Agreement with BioMarin Pharma 145 Relief Therapeutics Enters into Licensing Agreement with Merck Serono 146 EMD Millipore Enters into Licensing Agreement with Singulex 147 Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 148
Intrexon Enters into Licensing Agreement with Merck Serono 149 Symphogen Terminates Licensing Agreement with Merck for Anticancer Candidate Sym004 150 Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 152 EMD Serono Enters into Licensing Agreement with Sutro Biopharma 153 Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 155 EMD Serono Enters into Licensing Agreement with Mersana Therapeutics 157 Merck Serono Terminates Licensing Agreement with Ono Pharma for ONO-4641 158 MorphoSys Enters into Licensing Agreement with Merck Serono 159 Theratechnologies Terminates Collaboration And Licensing Agreement With EMD Serono For Tesamorelin 160 Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 162 Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 164 Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 165 Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 166 ObsEva Enters Into Licensing Agreement With Merck Serono 167 Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 168 Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 170 Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 172 Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 173 Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 174 Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 175 Merck Serono Amends Option and Licensing Agreement with Opexa Therapeutics 176 Merck Serono Terminates Licensing Agreement With Flamel Technologies 178 Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 179 EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 180 Materia Extends Licensing Agreement With Sigma Aldrich 181 Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 182 PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 183
Bionomics Terminates Licensing Agreement With Merck Serono 184 Ligand Pharma Enters Into Licencing Agreement With Merck 185 Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 186 EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 187 Sigma Life Science Enters Into Licensing Agreement With Kyoto University 188 Idera Pharma Terminates Licensing Agreement With Merck 189 Merck Serono Terminates Its Licensing Agreement With Newron For Safinamide 191 Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 192 Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 194 WntResearch Enters into Licensing Agreement with EMD Millipore 196 Affectis Pharma Enters Into Licensing Agreement With Merck Serono 197 Sigma Life Science Enters Into Licensing Agreement With King's College London 199 Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 200 Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 202 Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 203 Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin 205 Recordati Enters Into Licensing Agreement With Merck For Cardicor 206 Sanofi-aventis Enters Into Licensing Agreement With Merck Serono For AS703026 207 Merck Serono Enters Into Licensing Agreement With Sanofi-aventis For XL765 208 Plasticell Enters Into Licensing Agreement With Sigma-Aldrich 209 Millipore Enters into Licensing Agreement with Wayne State University 210 Allozyne Enters Into Licensing Agreement With Sigma-Aldrich 211 PregLem Enters Into Licensing Agreement With Merck Serono 212 University Of Illinois At Urbana-Champaign Enters Into Licensing Agreement With Sigma-Aldrich 213 EMD Millipore Enters Into Licensing Agreement With The Cleveland Clinic 214 Immunovaccine Enters Into License Agreement With Merck 215 Merck Serono Expands Licensing Agreement With Bionomics 216 Columbia Labs Renews Licensing Agreement With Merck Serono 217 Merck Terminates Worldwide Licensing Agreement With Lpath 218 Sigma-Aldrich Enters Into Licensing Agreement With CSIRO 219
Flexion Therapeutics Enters Into Licensing Agreement With Four Pharma Companies 220 Debt Offering 222 Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 222 Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 223 Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 224 Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 225 Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 226 Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 227 Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 228 Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 229 Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 230 Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 231 Sigma-Aldrich Completes An Underwritten Public Offering Of Senior Notes Due 2020 For US$300 Million 232 Asset Transactions 234 Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 234 Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 236 Eurofins Scientific To Acquire Assets Of Discovery And Development Solutions Business Of Merck 237 Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 239 Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 240 Noreva Pharma Acquires Dermo-Cosmetic Brands From Merck Medication 241 Acquisition 242 Merck Sells Bangalore Genei for USD1.5 Million 242 Merck May Sell Allergopharma for up to USD638 Million 243 Merck Acquires Sigma-Aldrich for USD17 Billion 244 Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 247 Merck And BASF Acquire Majority Stake In Innovation Lab 248 Albany Molecular Research Completes Acquisition Of Cedarburg Pharma For US$41 Million 249 EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 251 Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 252
Proxy Labs Acquires MicroSafe Laboratories From Millipore 253 Sigma-Aldrich Completes Acquisition Of BioReliance For US$350 Million 254 Sigma-Aldrich Acquires Vetec Quimica Fina 256 CAPS Holdings Terminates Acquisition Of Merck (Pty) 257 Sigma-Aldrich Acquires Resource Technology 258 Teva Pharma Industries Acquires THERAMEX From Merck Serono 259 Merck Acquires Beijing Skywing Technology For US$18.2 Million 261 Sigma-Aldrich Acquires Cerilliant From Argenta Partners 262 Merck Completes Acquisition Of Millipore 264 Sigma-Aldrich Acquires Ace Animals 267 BioReliance Acquires CynerGene 268 Merck KGaA - Key Competitors 269 Key Employees 270 Locations And Subsidiaries 271 Head Office 271 Other Locations & Subsidiaries 271 Appendix 284 Methodology 284 About GlobalData 284 Contact Us 284 Disclaimer 284
List of Tables Merck KGaA, Pharmaceuticals & Healthcare, Key Facts, 2015 1 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 13 Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 14 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 15 Merck KGaA, Deals By Therapy Area, 2010 to YTD 2016 16 Merck KGaA, Medical Devices Deals, 2010 to YTD 2016 18 Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 19 Merck KgaA Acquires SevenSeas Original Brand 32 Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 33
Asceneuron Raises USD30.6 Million in Series A Financing 34 TocopheRx Raises US$3.3 Million In Seed Financing 36 Asceneuron Raises US$6.4 Million In Seed Financing 37 VAXIMM Secures US$8 Million In Venture Financing 38 Merck Sells Its Pharma Operations To Nkunzi Investment And Omame 40 Merck Enters Into Licensing Agreement With BeiGene For BeiGene-290 41 Proteome Sciences Enters Into License Agreement With Sigma-Aldrich 42 PCAS Enters into Distribution Agreement with MilliporeSigma 43 MilliporeSigma Enters into Research Agreement with International Vaccine Institute 44 Selvita Enters into Agreement with Merck 45 Merck Enters into Agreement with University of Buea 46 Merck, Pfizer and Verastem Enter into Agreement 47 Merck Enters into Research Agreement with European Molecular Biology Labs 48 Threshold Pharma and Merck Terminates Agreement 49 Merck, Pfizer and Syndax Pharma Enter into Agreement 50 Selvita Enters into Development and Commercialization Agreement with Merck 51 Biothera Pharma Enters into Partnership with Merck 52 Sigma-Aldrich Enters into Agreement with Sanger Institute 53 Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 54 Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 55 Aeterna Zentaris Enters into Agreement with EMD Serono 56 Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 57 Lucigen Enters into Distribution Agreement with Sigma-Aldrich 58 Merck Serono Enters into Co-Development Agreement with MMV 59 Sigma-Aldrich Enters into Distribution Agreement with Roche 60 Merck Serono Terminates Agreement with Bristol-Myers Squibb 61 Merck Enters into Development Agreement with Precision Biologics 63 Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 64 Pfizer Enters into Co-Development Agreement with Merck 65 BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 67 Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 68
Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 69 Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 70 Lupin Enters into Co-Development Agreement with Merck Serono 71 Merck Serono Extends R&D Agreement with San Raffaele 72 Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 73 Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 74 Bionovis Enters into Agreement with Merck 75 EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 76 EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 78 KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 79 Biopharm Enters Into Research Agreement With Merck Serono 80 Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 81 EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 83 Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 84 Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 85 Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 87 Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 88 Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 90 Isu Abxis Enters into Co-Development Agreement with Merck 91 Luminex Extends Distribution Agreement With EMD Millipore 92 Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 93 Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 95 Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 96 Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 97 Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 99 EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 100 AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 101
EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 102 Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 103 Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 104 Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 105 TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 106 Genovis Enters Into Distribution Agreement With Sigma-Aldrich 107 Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 108 EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 110 EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 111 Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 112 Mapi Pharma Amends Co-Development Agreement with Merck 114 TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 115 Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 116 IntelliCell BioSciences Enters Into Co-Marketing Agreement With Millipore 118 f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 119 Emmaus Medical Terminates Co-Promotion Agreement With EMD Serono For Zorbtive 120 BASF Enters Into Distribution Agreement With Sigma-Aldrich 121 Lead Discovery Center Enters Into Agreement With Merck Serono 122 Merck Serono Enters Into Research Agreement With Philochem 123 Merck Serono Enters Into Co-Development Agreement With Sanofi-aventis 124 EMD Serono Enters Into Co-Marketing Agreement With Tercica 125 Merck Serono Extends Co-Development Agreement With INSpe And Department Of Neurology Of San Raffaele 126 Evotec Enters Into Collaboration With Merck KGaA 127 Domainex Enters Into Collaboration With Sigma-Aldrich 128 Sigma Life Science Enters Into Co-Marketing Agreement With JAX 129 Sigma Life Science Enters Into An Agreement With Autism Speaks 130 Ablynx Enters Into Second Co-Discovery And Co-Development Agreement With Merck Serono 131
EDELRIS Enters Into Collaboration With Merck Serono 132 Generex Biotech Enters Into Co-Marketing Agreement With Merck 133 Sigma Life Science Enters Into An Agreement With SwitchGear 134 Millipore Enters Into Collaboration With BioOutsource 135 Sigma-Aldrich Enters Into Distribution Agreement With New Mexico Highlands 136 Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim 137 Swedish Orphan Biovitrum Expands Distribution Agreement With Merck Serono 138 Eden Biodesign Enters Into A Collaboration With Millipore 139 Sigma-Aldrich Enters Into Commercialization Agreement With Pfizer 140 Sigma-Aldrich Enters Into Distribution Agreement With Eka Chemicals 141 BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono 142 Cancer Research And Cancer Research Technology Enter Into An Agreement With Merck 143 Merck Enters into Licensing Agreement with Weizmann Institute of Science 144 Merck Serono Terminates its Licensing Agreement with BioMarin Pharma 145 Relief Therapeutics Enters into Licensing Agreement with Merck Serono 146 EMD Millipore Enters into Licensing Agreement with Singulex 147 Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 148 Intrexon Enters into Licensing Agreement with Merck Serono 149 Symphogen Terminates Licensing Agreement with Merck for Anticancer Candidate Sym004 150 Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 152 EMD Serono Enters into Licensing Agreement with Sutro Biopharma 153 Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 155 EMD Serono Enters into Licensing Agreement with Mersana Therapeutics 157 Merck Serono Terminates Licensing Agreement with Ono Pharma for ONO-4641 158 MorphoSys Enters into Licensing Agreement with Merck Serono 159 Theratechnologies Terminates Collaboration And Licensing Agreement With EMD Serono For Tesamorelin 160 Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 162 Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 164 Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 165 Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger
Nuclease Technology 166 ObsEva Enters Into Licensing Agreement With Merck Serono 167 Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 168 Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 170 Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 172 Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 173 Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 174 Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 175 Merck Serono Amends Option and Licensing Agreement with Opexa Therapeutics 176 Merck Serono Terminates Licensing Agreement With Flamel Technologies 178 Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 179 EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 180 Materia Extends Licensing Agreement With Sigma Aldrich 181 Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 182 PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 183 Bionomics Terminates Licensing Agreement With Merck Serono 184 Ligand Pharma Enters Into Licencing Agreement With Merck 185 Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 186 EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 187 Sigma Life Science Enters Into Licensing Agreement With Kyoto University 188 Idera Pharma Terminates Licensing Agreement With Merck 189 Merck Serono Terminates Its Licensing Agreement With Newron For Safinamide 191 Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 192 Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 194 WntResearch Enters into Licensing Agreement with EMD Millipore 196 Affectis Pharma Enters Into Licensing Agreement With Merck Serono 197 Sigma Life Science Enters Into Licensing Agreement With King's College London 199 Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 200 Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 202
Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 203 Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin 205 Recordati Enters Into Licensing Agreement With Merck For Cardicor 206 Sanofi-aventis Enters Into Licensing Agreement With Merck Serono For AS703026 207 Merck Serono Enters Into Licensing Agreement With Sanofi-aventis For XL765 208 Plasticell Enters Into Licensing Agreement With Sigma-Aldrich 209 Millipore Enters into Licensing Agreement with Wayne State University 210 Allozyne Enters Into Licensing Agreement With Sigma-Aldrich 211 PregLem Enters Into Licensing Agreement With Merck Serono 212 University Of Illinois At Urbana-Champaign Enters Into Licensing Agreement With Sigma-Aldrich 213 EMD Millipore Enters Into Licensing Agreement With The Cleveland Clinic 214 Immunovaccine Enters Into License Agreement With Merck 215 Merck Serono Expands Licensing Agreement With Bionomics 216 Columbia Labs Renews Licensing Agreement With Merck Serono 217 Merck Terminates Worldwide Licensing Agreement With Lpath 218 Sigma-Aldrich Enters Into Licensing Agreement With CSIRO 219 Flexion Therapeutics Enters Into Licensing Agreement With Four Pharma Companies 220 Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 222 Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 223 Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 224 Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 225 Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 226 Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 227 Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 228 Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 229 Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 230 Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 231 Sigma-Aldrich Completes An Underwritten Public Offering Of Senior Notes Due 2020 For US$300 Million 232 Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 234 Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 236
Eurofins Scientific To Acquire Assets Of Discovery And Development Solutions Business Of Merck 237 Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 239 Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 240 Noreva Pharma Acquires Dermo-Cosmetic Brands From Merck Medication 241 Merck Sells Bangalore Genei for USD1.5 Million 242 Merck May Sell Allergopharma for up to USD638 Million 243 Merck Acquires Sigma-Aldrich for USD17 Billion 244 Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 247 Merck And BASF Acquire Majority Stake In Innovation Lab 248 Albany Molecular Research Completes Acquisition Of Cedarburg Pharma For US$41 Million 249 EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 251 Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 252 Proxy Labs Acquires MicroSafe Laboratories From Millipore 253 Sigma-Aldrich Completes Acquisition Of BioReliance For US$350 Million 254 Sigma-Aldrich Acquires Vetec Quimica Fina 256 CAPS Holdings Terminates Acquisition Of Merck (Pty) 257 Sigma-Aldrich Acquires Resource Technology 258 Teva Pharma Industries Acquires THERAMEX From Merck Serono 259 Merck Acquires Beijing Skywing Technology For US$18.2 Million 261 Sigma-Aldrich Acquires Cerilliant From Argenta Partners 262 Merck Completes Acquisition Of Millipore 264 Sigma-Aldrich Acquires Ace Animals 267 BioReliance Acquires CynerGene 268 Merck KGaA, Key Competitors 269 Merck KGaA, Key Employees 270 Merck KGaA, Subsidiaries 271
List of Figures Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 13 Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 14 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 15 Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 16 Merck KGaA, Medical Devices Deals, 2010 to YTD 2016 18
Ask a sample and any further questions, please feel free to contact us: Tel: +00-1-626-3463946 - U.S Email: shirley@marketresearchreportstore.com Web: http://www.marketresearchreportstore.com/